Insomnia
Conditions
Interventions
Cognitive Behavioral Therapy (CBT) Group:Prior to the commencement of the study, the three participating therapists underwent centralized training to ensure they fully understood the research protocol
Traditional Intervention Group:Patients in the insomnia disorder group were administered Eszopiclone tablets (Manufacturer: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Approval Number: National Medicine Approval H20090209
Specification: 2 mg) orally at 2 mg per dose. For patients with poorer constitution or elderly patients, the dose could be reduced to 1 mg per dose initially, and then increased to 2 mg per dose based
Sponsors
The Second People's Hospital of Hunan Province (Hunan Provincial Brain Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meeting the diagnostic criteria for sleep disorders according to ICD-10; 2. Disease duration of at least 3 months; 3. Age between 18 and 75 years; 4. No use of relevant medications within 4 weeks prior to enrollment; 5. Intact self-awareness, full understanding of the study content, willingness to participate and complete the entire study, and provision of signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Presence of serious organic diseases such as major organ pathologies or tumors; 2. Presence of hematological diseases; 3. Presence of severe endocrine disorders; 4. Presence of psychiatric disorders; 5. Currently lactating or pregnant; 6. Presence of immune-related diseases; 7. Communication barriers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pittsburgh Sleep Quality Index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Insulin-like Growth Factor 1 Gene; | — |
Countries
China
Contacts
Public ContactZengXianXiang
The Second People's Hospital of Hunan Province (Hunan Provincial Brain Hospital)
Outcome results
None listed